Forest Lexapro for panic disorder
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Forest's April 30 submission of Lexapro (escitalopram) for the treatment of panic disorder is the fourth supplement for the antidepressant, which has had one of the strongest launches in history following its Aug. 14, 2002 approval for treatment of depression. The drug gained a maintenance claim Aug. 29, 2002, and an oral solution formulation was cleared in November 2002. An sNDA for generalized anxiety disorder was submitted in November 2002 and a social anxiety disorder filing is slated for "late in the fiscal year." Forest projects that the Celexa follow-on will lead the selective serotonin reuptake inhibitor market by 200
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.